Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
September 5, 2025
by lezhi
Summary and Brief Analysis of New Drugs Approved by NMPA in 2021
With the revision and promulgation of the Drug Administration Law in 2019, Chinese drug review and approval system has been strengthened and improved.
March 29, 2022
by PharmaSources/zhulikou431
GSK establishes AI hub in London to discover new drugs
GlaxoSmithKline (GSK) has opened a £10m research hub in King’s Cross, London, UK, to leverage artificial intelligence (AI) for the discovery of new drugs to treat cancer and other diseases.
September 7, 2020
by pharmaceutical-technology
Drug Trials Snapshots
Drug Trials Snapshots provide consumers and healthcare professionals with concise information about who participated in clinical trials that supported the FDA approval of new drugs.
March 2, 2020
by prnasia
Important Progresses of New Drugs Marketed in China in 2019
Imported Drugs:1、Novartis CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market Novartis f
January 7, 2020
by En-CPhI.CN
J&J launches research consortium for new drugs against TB
Johnson & Johnson (J&J) has formed an international research consortium to focus on the discovery and development of new antibiotics to treat tuberculosis (TB).
July 25, 2019
by pharmaceutical-technology
Lilly to focus on new drugs in China, unload antibiotics brands and manufacturing facility for $375M
Eli Lilly is taking one step out of China so it can gain a firmer foothold with the other. Amid a national clampdown on antibiotics overuse, the U.S. pharma is selling Chinese rights to two legacy antibiotics and a manufacturing facility in a deal worth $
April 24, 2019
by fiercepharma
Chinese patients to get new drugs before UK after Brexit – says CEO
US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.
February 15, 2019
by pharmaphorum
A Review of the Chinese-produced New Drugs Marketed in 2018
Biological Drugs Accounted for Half of the Total; Avitinib May Become the First One Marketed in 2019
January 21, 2019
by PharmaSources/Caicai
Chinese-produced New Drugs Approved for Marketing in 2018
Chinese-produced New Drugs Approved for Marketing in 2018
January 21, 2019
by PharmaSources/caicai
Chinese-produced new drugs to be marketed soon in 2019
Chinese-produced new drugs to be marketed soon in 2019
January 21, 2019
by PharmaSources/Caicai
AstraZeneca H1 results: new drugs and emerging markets fuel growth
AstraZeneca has announced new medicines and emerging markets have driven its growth in the first half (H1) of 2018. This has been partially offset by the loss of Crestor exclusivity in Europe and Japan.
July 30, 2018
by pharmaceutical-technology